New hope for kids with Hard-to-Control seizures?
NCT ID NCT07594158
First seen May 19, 2026 · Last updated Jun 22, 2026 · Updated 7 times
Summary
This Phase 3 trial tests the drug cenobamate in 20 Japanese children aged 2 to 17 who have partial-onset seizures not controlled by current treatments. The main goal is to see if the drug is safe and tolerable. Participants take cenobamate tablets daily, with doses adjusted based on response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARTIAL EPILEPSY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Japan Red Cross Fukuoka Hospital
RECRUITINGFukuoka, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cenobamate (tablet)
What this could lead to
If it works, this could provide a new treatment option to help control partial seizures in children who don't respond to current medications.
What could go wrong
This is a small, open-label trial (no placebo) with only 20 participants, so results may not apply broadly. Side effects are possible, and the drug may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.